Laboratory Corporation of America Holdings (LH) has risen sharply, recording gains of 2.83% in the past 4 weeks. However, the stock has corrected -0.5% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.78% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.89% and the 50-Day Moving Average is 4.75%. Laboratory Corporation of America Holdings (NYSE:LH): On Fridays trading session , Opening price of the stock was $140.41 with an intraday high of $140.95. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $139.88. However, the stock managed to close at $140.05, a loss of 0.66% for the day. On the previous day, the stock had closed at $140.98. The total traded volume of the day was 613,395 shares.
The company Insiders own 1.14% of Laboratory Corporation of America Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -43.48% . Institutional Investors own 95.21% of Laboratory Corporation of America Holdings shares. During last six month period, the net percent change held by insiders has seen a change of -60.37%. Also, Equity Analysts at the Brokerage Firm, UBS, maintains their rating on the shares of Laboratory Corporation of America Holdings (NYSE:LH). UBS has a Neutral rating on the shares. As per the latest research report, the brokerage house raises the price target to $137.5 per share from a prior target of $125. The rating by the firm was issued on July 28, 2016.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.